Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5773-5780

  Berry, Suzanne E ^a,b   Davis, Thomas W ^a   Schupp, Jane E ^a   Hwang, Hwa Shin ^a   de Wind, Niels ^c   Kinsella, Timothy J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; DNA; IDOXURIDINE; RADIOSENSITIZING AGENT; THYMIDINE DERIVATIVE; TIOGUANINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BASE MISPAIRING; CELL CYCLE; CELL CYCLE G2 PHASE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; EMBRYO; ENDOMETRIUM CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BASE PAIR MISMATCH; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TRANSFORMED; DEOXYCYTOSINE NUCLEOTIDES; DNA; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IDOXURIDINE; KINETICS; MICE; MICE, KNOCKOUT; MUTS HOMOLOG 2 PROTEIN; PROTO-ONCOGENE PROTEINS; RADIATION-SENSITIZING AGENTS; THIOGUANINE; THYMINE NUCLEOTIDES;

EID: 0034667429     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents
2. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine
3. Role of mismatch repair in apoptosis induced by methyltriazines
4. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
5. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaloplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
6. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
7. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea
8. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line
9. A mutator phenotype characterizes one of two complementation groups in human cells tolerant to methylation damage
10. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
11. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
12. The role of DNA mismatch repair in drug resistance
13. Involvement of the DNA mismatch repair system in antineoplastic drug resistance
14. Challenging drug resistance in cancer therapy
15. The effect of a homozygous hMLH1 mutation on antitumor alkylating agent sensitivity
16. The role of DNA mismatch repair in platinum drug resistance
17. Mutations predisposing to hereditary nonpolyposis colorectal cancer
18. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
19. Clues to the pathogenesis of familial colorectal cancer
20. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome
21. + tumor cells
22. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
23. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer
24. Frequent microsatellite instability in primary small cell lung cancer
25. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer
26. Genetic instability of microsatellites in endometrial carcinoma
27. Mutator phenotype in a subset of chronic lymphocytic leukemia
28. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia
29. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
30. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers
31. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability
32. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity. DNA incorporation, and radiosensitization in human colon cancer cells
33. Enhancement of X Ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs
34. Mechanism of radiosensitization by halogenated pyrimidines: Effect of BrdUrd on radiation induction of DNA and chromosome damage and its correlation with cell killing
35. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine
36. Halogen anion formation in 5-halouracil films: X rays compared to subionization electrons
37. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine
38. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. Radiosensitization of human colon cancer cells by bromodeoxyuridine
39. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer
40. 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins
41. The results of primary culture of endometrial adenocarcinoma and characterization of its established line
42. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability
43. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6
44. 1 restriction point into S-phase: Implications for fluoropyrimidine radiosensitization
45. 2-M cell cycle checkpoint arrest following ionizing radiation
46. 2 cell cycle checkpoint
47. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine
48. Involvement of the mismatch repair system in Temozolomide-induced apoptosis
49. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease free survival
50. Reduced expression of hMLH1 and hGTBP/hMSH6: A risk factor for head and neck cancer
51. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma
52. Mouse models for hereditary nonpolyposis colorectal cancer
53. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer; Implications for clinical predisposition testing
54. Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer
55. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
56. A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer
57. Clinical experience with intravenous radiosensitizers in unresectable sarcomas
58. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver
59. A phase I study of intra-arterial iododeoxyuridine in patients with colorectal liver metastases
60. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion
61. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma
62. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I-II study
63. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
64. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT116
65. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues
66. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) as a prodrug for IdUrd-radiosensitization in U251 human glioblastoma xenografts